$PHGE News

Last published 1mo ago

1mo agoHLSQ PHGETessera Defense and Homeland Security CEO Issues Letter to ShareholdersGlobeNewswireNETANYA, Israel, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Tessera Defense and Homeland Security Inc. (NYSE:HLSQ) ("Tessera" or "the Company") formerly BiomX Inc (NYSE:PHGE), today released the following
2mo agoPHGEBiomX: Zorronet Launches No-Code Control Over AI-Powered Autonomous Response WorkflowsGlobeNewswireNETANYA, Israel, Sept. 04, 2026 (GLOBE NEWSWIRE) -- BiomX Inc., to be renamed Tessera Defense and Homeland Security Inc. effective September 11, 2026 (NYSE:PHGE, HLSQ from September 11, 2026)) ("BiomX" or the
2mo agoPHGEBiomX Inc. to Become Tessera Defense and Homeland Security Inc.GlobeNewswireNETANYA, Israel, Sept. 01, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) (the "Company") today announced that it will change its corporate name to Tessera Defense and Homeland Security Inc., effective at
2mo agoPHGEBiomX Subsidiary Zorronet Receives Approximately $300,000 Purchase Order to Build Unified Operational Environment at Defense Technology Test and Evaluation SiteGlobeNewswireNETANYA, Israel, Aug. 14, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a company focused on defense, security and critical infrastructure technologies, today announced
3mo agoPHGEBiomX Acquires 10% Stake in Motomea, Inventor of Advanced Electric Motor Technologies for Drone and Autonomous SystemsGlobeNewswireNETANYA, Israel, Aug. 05, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a defense technology company building a portfolio of technologies to detect, analyze and respond to
3mo agoPHGEBiomX And Water.IO Agree To Updated Zorronet Acquisition TermsGlobeNewswireNETANYA, Israel, July 28, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a company focused on defense, security, and critical infrastructure technologies, today announced
3mo agoPHGEBiomX Subsidiary Zorronet Expands European Presence Through Two Strategic Collaborations in EuropeGlobeNewswireNETANYA, Israel, July 24, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company") today announced that its subsidiary, Zorronet Ltd. ("Zorronet"), has entered into a
4mo agoPHGEBiomX: Zorronet Completes Transition to New Advanced Data Center Supporting Business Expansion and Enhanced AI CapabilitiesGlobeNewswireNETANYA, Israel, July 10, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a company focused on defense, security, and critical infrastructure technologies, today announced
4mo agoPHGEBiomX Signs Non-Binding Letter of Intent to Acquire Control of Revenue-Generating Security Infrastructure and Systems Integration Company, Expanding Its Security Platform with Critical Infrastructure and Secure-Site Integration CapabilitiesGlobeNewswireNETANYA, Israel, July 08, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a company focused on acquiring and further developing technologies that identify, analyze, protect
4mo agoPHGEBiomX: Subsidiary Zorronet Commences Installation and Operation of AI-Powered Detection Systems Under Israel Railways AgreementGlobeNewswireNETANYA, Israel, July 06, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), announced today following its April 16, 2026 announcement that its wholly-owned subsidiary Zorronet
4mo agoPHGEBiomX: Next-Gen Counter Drone Solutions will be Showcased by DFSL at ISC 2026GlobeNewswireNETANYA, Israel, June 24, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company") today announced that its majority-owned subsidiary company DFSL Ltd. ("DFSL") will showcase
4mo agoPHGEBiomX Provides Update on Defense Technology Portfolio and Growth StrategyGlobeNewswireNETANYA, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE), a company that develops and acquires technologies for defense, security, and first-response markets, today announced that it has posted an
5mo agoPHGEBiomX Announces NYSE American Acceptance of Plan to Regain ComplianceGlobeNewswireNETANYA, Israel, June 12, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company") today announced that the Company's previously-submitted plan (the "Plan") to regain compliance with NYSE American
5mo agoPHGEBiomX: Zorronet's AI Security Experts Provide In-Depth Review on Why Security AI Must Move Beyond Detection to Understanding in High-Stakes Global EventsGlobeNewswireNETANYA, Israel, June 11, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a company focused on defense, security, and critical infrastructure technologies, today announced the publication of
5mo agoPHGEAnother Prominent Defense Technology Leader Joins BiomX: Prof. Gabby Sarusi, Former VP and Chief Scientist at ElbitGlobeNewswireNETANYA, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), today announced the appointment of Prof. Gabby Sarusi as Strategic Advisor to the Company. Prof. Sarusi will advise
5mo agoPHGEZorronet Brings Autonomous C5ISR to Hardened Sites Without Public Cloud DependenceGlobeNewswireNETANYA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), today announced the expansion of its Zorronet subsidiary's autonomous C5ISR suite to support fully secure
5mo agoPHGEBiomX Appoints IDF Colonel (res.) Roy Timor-Rousso as Chief Business Officer to Strengthen Defense & Security OperationsGlobeNewswireNETANYA, Israel, May 27, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), today announced the appointment of Roy Timor-Rousso as Chief Business Officer (CBO), adding senior business &
6mo agoPHGEBiomX's Zorronet Puts Full AI Command-and-Control in the Palm of Your HandGlobeNewswireNETANYA, Israel, May 06, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company") today announced that its Zorronet subsidiary has launched a secure mobile application that brings its system directly
6mo agoPHGEZorronet Delivers 98% Success in Israel Railways Pilot, Awarded Framework Supply Agreement for AI-Powered Detection SystemsGlobeNewswireNETANYA, Israel, April 16, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company") today highlighted the successful deployment of its Zorronet subsidiary in collaboration with Israel Railways,
7mo agoPHGEBiomX Accelerates Defense Technology Buildout with DFSL AcquisitionGlobeNewswireNETANYA, Israel, April 13, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company") today announced that it has accelerated the exercise of its previously disclosed exclusive option and
7mo agoPHGEBiomX Acquires Zorronet, Autonomous AI Command-and-Control Platform for Real-Time Defense and Security ApplicationsGlobeNewswireNETANYA, Israel and REHOVOT, Israel, April 10, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) (the "Company") today announced that it has completed the acquisition of 100% of Zorronet from Water.io (TASE: WATR). This
7mo agoPHGEBiomX Obtains Option to Acquire Control of Israeli Laser-Radar Counter-Drone SystemGlobeNewswireNETANYA, Israel, March 31, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) today announced that it has entered into an option agreement to acquire control of DFSL, a developer of proprietary LADAR (Laser Radar)–based
7mo agoPHGEBiomX Adds Former Mossad Deputy to Advisory BoardGlobeNewswireNETANYA, Israel, March 30, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE), today announced the appointment of Dr. Ehud (Udi) Levi to its newly formed Advisory Board. Dr. Levi will support the Company in evaluating
7mo agoPHGEBiomX Inc. Received NYSE American Notification Letter Regarding Stockholders' Equity DeficiencyGlobeNewswireNETANYA, Israel, March 27, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) (the "Company") today announced that on March 25, 2026, the Company received a notice from the staff of NYSE American LLC (the "NYSE American")
7mo agoPHGEBiomX Launches Security Subsidiary in Israel and Will Initially Invest Over $3 million In Its OperationsGlobeNewswireNETANYA, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) today announced the launch of X Security & Defense LTD., a new wholly-owned subsidiary. The company will finance its 2026 operations with
7mo agoPHGEBiomX CEO Issues Letter to StockholdersPR NewswireBiomX Inc. (NYSE American: PHGE), today released the following letter from its Chief Executive Officer to stockholders. Dear Stockholders, Over the...
8mo agoPHGEBiomX Names Michael Oster as Chief Executive Officer, David Rokach Chief Financial Officer to Support Next Phase of GrowthPR NewswireBiomX Inc. (NYSE American: PHGE), a clinical-stage company developing natural and engineered phage therapies designed to target and destroy harmful...
9mo agoPHGEBiomX Issues Statement Regarding Recent Common Stock Trading ActivityGlobeNewswireNESS ZIONA, Israel, Jan. 27, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic
10mo agoPHGEBiomX Announces $3.0 Million Private PlacementGlobeNewswireNESS ZIONA, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic
11mo agoPHGEBiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal ReviewGlobeNewswireFollowing internal analysis and Data Monitoring Committee (DMC) feedback, the Company has elected to discontinue the BX004 Cystic Fibrosis (CF) Phase 2b trial BiomX continues to see potential in BX011, its phage
11mo agoPHGEBiomX Provides Update on BX004 Phase 2b Trial in Cystic FibrosisGlobeNewswireThe Company continues working with the third-party manufacturer to address recent FDA follow-up information requests which are required to lift the clinical hold concerning the nebulizer device used in the Phase 2b trial
12mo agoPHGEBiomX Inc. Announces 1-for-19 Reverse Stock SplitGlobeNewswireNESS ZIONA, Israel, Nov. 14, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic
12mo agoPHGEBiomX Reports Third Quarter 2025 Financial Results and Provides Program UpdatesGlobeNewswirePositive FDA feedback confirms clear clinical pathway for BX011 targeting S. aureus in Diabetic Foot Infections, building on Company's prior Phase 2 success BiomX expects FDA feedback on BX004 clinical hold imminently;
1y agoPHGEBiomX to Report Third Quarter 2025 Financial Results and Program Updates on November 12, 2025GlobeNewswireNESS ZIONA, Israel, Nov. 05, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic
1y agoPHGEBiomX Announces Positive FDA Feedback Supporting Next-Generation Phage Cocktail Program for Diabetic Foot InfectionsGlobeNewswireNESS ZIONA, Israel, Nov. 04, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic
1y agoPHGEBiomX Provides a Program Update and Announces New FDA Feedback Potentially Expanding BX004 Development PathwaysGlobeNewswireBiomX believes that it has fully addressed the FDA's queries related to the third-party nebulizer used to deliver BX004, which are narrow in scope; an additional FDA request for limited technical clarifications on the
1y agoPHGEBiomX CEO to Present at H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewswireNESS ZIONA, Israel, Sept. 04, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE), a clinical-stage company advancing natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that
1y agoPHGEBiomX Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic FibrosisGlobeNewswireU.S. FDA has placed a clinical hold on the Phase 2b study as it reviews data submitted by BiomX on third-party nebulizer used to deliver BX004; no concerns were raised in the clinical hold notification regarding the
1y agoPHGEBiomX Inc. (PHGE) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
1y agoPHGEBiomX Reports Second Quarter 2025 Financial Results and Provides Program UpdatesGlobeNewswirePositive Phase 2 results for BX211 demonstrated >40% wound size reduction vs. placebo in diabetic foot osteomyelitis patients; Planning underway for potential registrational study Nature Communications publication of
1y agoPHGEBiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025GlobeNewswireNESS ZIONA, Israel, Aug. 06, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic
1y agoPHGEBiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic FibrosisGlobeNewswireFirst patient dosing in Company's Phase 2b trial marks pivotal milestone in phage therapy development program targeting antibiotic-resistant lung infections in Cystic Fibrosis patients; topline results are expected in Q1
1y agoPHGEBiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 ConferenceGlobeNewswireNESS ZIONA, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic
1y agoPHGEBiomX Reports First Quarter 2025 Financial Results and Provides Business and Program UpdatesGlobeNewswireIn March 2025, BiomX announced positive topline results of the phase 2 trial evaluating BX211 for the treatment of diabetic foot osteomyelitis (DFO) BX004 Phase 2b study in Cystic Fibrosis (CF) on track to report
1y agoPHGEBiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025GlobeNewswireNESS ZIONA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic
1y agoPHGEBiomX Announces Compliance with NYSE Guidelines on Audit Opinion DisclosureGlobeNewswireNESS ZIONA, Israel, April 01, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic
1y agoPHGEBiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)GlobeNewswireBX211 was safe and well-toleratedBX211 produced sustained and statistically significant1 Percent Area Reduction (PAR) of ulcer size (p = 0.046 at week 12; p=0.052 at week 13), with a separation from placebo starting at
1y agoPHGEBiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program UpdatesGlobeNewswireIn February 2025, BiomX announced a series of financings with total gross proceeds of approximately $12 million to support completion of Phase 2b study of BX004; topline results anticipated in Q1 2026Topline Phase 2
1y agoPHGEBiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025GlobeNewswireNESS ZIONA, Israel, March 19, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic
1y agoPHGEBiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 MillionGlobeNewswireProceeds to support advancement of BX004 program through Phase 2b study topline results in cystic fibrosis (CF) patients, anticipated in Q1 2026 Financing will also support analysis of real-world evidence in people